The Medical Advisor

If you trying to understand and looking for evidence about time-restricted eating, you've come to the right place. Time-restricted eating is just what it sounds like. It's a form of intermittent fasting where you eat all of your meals for the day within a restricted window of time, ranging from two to eight hours. That means you're avoiding food (fasting) for 16 to 22 consecutive hours. Eating within a four- to six-hour window is likely close to metabolic ideal for most. As noted in the paper "A Time to Fast," published in the November 2018 issue of Science : "Adjustment of meal size and frequency have emerged as powerful tools to ameliorate and postpone the onset of disease and delay aging, whereas periods of fasting, with or without energy intake, can have profound health benefits. The underlying physiological processes involve periodic shifts of metabolic fuel sources, promotion of repair mechanisms, and the optimization of energy utilization for cellular ...

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. There’s been such a rush on the drugs that the U.S. Food and Drug Administration lists both Ozempic and Wegovy a...

Introduction In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management . Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors. GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight , alongside me...

⚠️ IMPORTANT MEDICAL DISCLAIMER: Retatrutide is an investigational drug and is not yet FDA-approved for weight loss or type 2 diabetes. The information below is for educational and news-tracking purposes based on clinical trial data published in 2026. Always consult a healthcare provider for currently available, approved weight-loss treatments. The landscape of medical weight loss is shifting at a breakneck pace. While semaglutide (Wegovy) and tirzepatide (Zepbound) dominated headlines over the last few years, a new powerhouse is poised to redefine obesity treatment: Retatrutide . Developed by Eli Lilly, Retatrutide is a "triple-agonist" peptide targeting three hunger-regulating receptors. With highly anticipated Phase 3 topline data officially published in early 2026, this drug is shaping up to be the most potent weight-loss medication ever developed. Here is your comprehensive, regularly updated hub on Retatrutide’s 2026 trial results, FDA time...

The World Health Organization has finally gotten around to declaring the popular artificial sweetener aspartame a potential carcinogen (1). Dr Mercola warned about aspartame’s cancer-causing potential on his site over 25 years ago, in his best-selling book, “Sweet Deception: Why Splenda, NutraSweet, and the FDA May Be Hazardous to Your Health,” in 2006, and in an article he wrote for The Huffington Post (2). It’s since been deleted — but you can see just how long this danger has been known. The ruling comes from sources with WHO’s International Agency for Research on Cancer (IARC), who said aspartame will be listed as “possibly carcinogenic to humans” in July 2023 (3). Additional findings from the Joint WHO and Food and Agriculture Organization's Expert Committee on Food Additives (JECFA), which is in the process of updating its aspartame risk assessment, are also expected. (4) Aspartame’s Cancer Link Known for Decades Despite aspartame’s approval, by 1987 a series of investigative...